Étude de variabilité photométrique infrarouge de naines brunes

Les naines brunes sont des objets astronomiques de faible masse ( 0.012 - 0.075 M_Sun ) et de basse température ( T < 3,500 K ). Bien qu’elles se forment comme des étoiles, c’est-à-dire par l’effondrement d’un nuage de gaz moléculaire, les naines brunes n’ont pas une masse suffisante pour entretenir des réactions de fusion nucléaire en leur coeur. Les naines brunes relativement chaudes (type L) sont recouvertes de nuages de poussière mais ces derniers disparaissent progressivement de l’atmosphère lorsque la température chute sous les 1,500 K (type T). Les naines brunes près de la transition L/T devraient donc être partiellement recouvertes de nuages. De par leur rotation relativement rapide (2 h - 12 h), le couvert nuageux inhomogène des naines brunes devrait produire une variabilité photométrique observable en bande J (1.2 um), la longueur d’onde à laquelle les nuages ont la plus forte opacité. Ce mémoire présente les résultats d’une recherche de variabilité photométrique infrarouge pour une dizaine de naines brunes de type spectral près de la transition L/T. Les observations, obtenues à l’Observatoire du Mont-Mégantic, ont permis le suivi photométrique en bande J de neuf cibles. Une seule d’entre elles, SDSS J105213.51+442255.7 (T0.5), montre des variations périodiques sur une période d’environ 3 heures avec une amplitude pic-à-pic variant entre 40 et 80 mmag. Pour les huit autres cibles, on peut imposer des limites (3 sigma) de variabilité périodique à moins de 15 mmag pour des périodes entre 1 et 6 heures. Ces résultats supportent l’hypothèse qu’un couvert nuageux partiel existe pour des naines brunes près de la transition L/T mais ce phénomène demeure relativement peu fréquent.Brown dwarfs are astronomical objects of low mass ( 0.012 - 0.075 M_Sun ) and low temperature ( T < 3,500 K ). While they do form like stars through gravitational collapse of a molecular gas cloud, they do not have sufficient mass to sustain nuclear fusion reactions in their core. Relatively hot brown dwarfs (type L) are covered by an homogeneous dust cloud cover that progressively disappears from their atmosphere when the temperature falls below 1,500 K (type T). Therefore, brown dwarfs near the L/T transition should be partially covered with clouds. Due to the fast rotation of brown dwarfs (2 h - 12 h), this inhomogeneous cloud cover should produce photometric variability observable in the J band (1.2 um), the wavelength at which the clouds have the strongest opacity. This thesis presents the results of a search for infrared photometric variability in brown dwarfs near the L/T transition. The observations, obtained at the Observatoire du Mont-Mégantic, have allowed the photometric follow-up of nine targets in the J band. Only one of them, SDSS J105213.51+442255.7 (T0.5), showed periodic variations with a period of about 3 hours with a peak-to-peak amplitude ranging from 40 to 80 mmag. For the remaining eight targets, we can place upper limits (3 sigma) of 15 mmag for the amplitude of periodic variability over a period range betwen 1 and 6 hours. While these results support the hypothesis that partial dust cloud covers do exist among L/T dwarfs, this phenomenon is by no means ubiquitous

Cardiovascular therapy use, modification, and in-hospital death in patients with COVID-19: A cohort study

AIMS: To assess the associations of exposure and modifications in exposure (i.e., discontinuation on admission, initiation during hospitalization) to eight common cardiovascular therapies with the risk of in-hospital death among inpatients with coronavirus disease 2019 (COVID-19). METHODS: In this observational study including 838 hospitalized unvaccinated adult patients with confirmed COVID-19, the use of cardiovascular therapies was assessed using logistic regression models adjusted for potential confounders. RESULTS: No cardiovascular therapy used before hospitalization was associated with an increased risk of in-hospital death. During hospitalization, the use of diuretics (aOR 2.59 [1.68–3.98]) was associated with an increase, and the use of agents acting on the renin-angiotensin system (aOR 0.39 [0.23–0.64]) and lipid-lowering agents (aOR 0.41 [0.24–0.68]) was associated with a reduction in the odds of in-hospital death. Exposure modifications associated with decreased survival were the discontinuation of an agent acting on the renin-angiotensin system (aOR 4.42 [2.08–9.37]), a β-blocker (aOR 5.44 [1.16–25.46]), a lipid-modifying agent (aOR 3.26 [1.42–7.50]) or an anticoagulant (aOR 5.85 [1.25–27.27]), as well as the initiation of a diuretic (aOR 5.19 [2.98–9.03]) or an antiarrhythmic (aOR 6.62 [2.07–21.15]). Exposure modification associated with improved survival was the initiation of an agent acting on the renin-angiotensin system (aOR 0.17 [0.03–0.82]). CONCLUSION: In hospitalized and unvaccinated patients with COVID-19, there was no detrimental association of the prehospital use of any regular cardiovascular medication with in-hospital death, and these therapies should be continued as recommended

Immunosuppressant drugs and quality-of-life outcomes in kidney transplant recipients: An international cohort study (EU-TRAIN)

Immunosuppressant; Quality of life; TransplantationImmunosupressor; Qualitat de vida; TrasplantamentInmunosupresor; Calidad de vida; TrasplanteIntroduction: Patient-Reported Outcomes (PRO) integrate a wide range of holistic dimensions that arenot captured within clinical outcomes. Particularly, from induction treatment to maintenance therapy, patient quality-of-life (QoL) of kidney transplant recipients have been sparsely investigated in international settings. Methods: In a prospective, multi-centric cohort study, including nine transplant centers in four countries, we explored the QoL during the year following transplantation using validated elicitation instruments (EQ-5D-3L index with VAS) in a population of kidney transplant patients receiving immunosuppressive therapies. Calcineurin inhibitors (tacrolimus and ciclosporin), IMPD inhibitor (mycophenolate mofetil), and mTOR inhibitors (everolimus and sirolimus) were the standard-of-care (SOC) medications, together with tapering glucocorticoid therapy. We used EQ-5D and VAS data as QoL measures alongside descriptive statistics at inclusion, per country and hospital center. We computed the proportions of patients with different immunosuppressive therapy patterns, and using bivariate and multivariate analyses, assessed the variations of EQ-5D and VAS between baseline (i.e., inclusion Month 0) and follow up visits (Month 12). Results: Among 542 kidney transplant patients included and followed from November 2018 to June 2021, 491 filled at least one QoL questionnaire at least at baseline (Month 0). The majority of patients in all countries received tacrolimus and mycophenolate mofetil, ranging from 90.0% in Switzerland and Spain to 95.8% in Germany. At M12, a significant proportion of patients switched immunosuppressive drugs, with proportion varying from 20% in Germany to 40% in Spain and Switzerland. At visit M12, patients who kept SOC therapy had higher EQ-5D (by 8 percentage points, p < 0.05) and VAS (by 4 percentage points, p < 0.1) scores than switchers. VAS scores were generally lower than EQ-5D (mean 0.68 [0.5–0.8] vs. 0.85 [0.8–1]). Discussion: Although overall a positive trend in QoL was observed, the formal analyses did not show any significant improvements in EQ-5D scores or VAS. Only when the effect of a therapy use was separated from the effect of switching, the VAS score was significantly worse for switchers during the follow up period, irrespective of the therapy type. If adjusted for patient characteristics and medical history (e.g., gender, BMI, eGRF, history of diabetes), VAS and EQ-5D delivered sound PRO measures for QoL assessments during the year following renal transplantation.The project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 754995. Open access funding by University of Lausanne

Feasibility study of a CO2-based system in NEST

The NEST building laboratory of Empa and Eawag is a modular research and innovation demonstrator where new technologies, materials and systems are tested, researched, honed and validated in realistic conditions. In the NEST concept, only the supporting structure is permanent and all the habitable units are interchangeable. Moreover, the site is hosting an energy research and technology transfer platform (ehub) aiming at optimizing energy management at district level and a demonstrator for future mobility working without fossil energy (move). Therefore, the NEST research platform seems to be an appropriate place for the implementation of a demonstrator of advanced 4th Generation District Heating and Cooling systems (4G-DHC). This study demonstrates the feasibility of a CO2-based district energy network in NEST. The report includes a concise project plan and budget positions for the concept, planning, installation and operation phase